Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. More Details
Reasonable growth potential and fair value.
Share Price & News
How has Clinigen Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CLIN is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: CLIN's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
7 Day Return
GB Life Sciences
1 Year Return
GB Life Sciences
Return vs Industry: CLIN underperformed the UK Life Sciences industry which returned 13.6% over the past year.
Return vs Market: CLIN underperformed the UK Market which returned 22.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Clinigen Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StReflecting on Clinigen Group's (LON:CLIN) Share Price Returns Over The Last Three Years
1 month ago | Simply Wall StClinigen Group (LON:CLIN) Has A Somewhat Strained Balance Sheet
2 months ago | Simply Wall StCan Mixed Fundamentals Have A Negative Impact on Clinigen Group plc (LON:CLIN) Current Share Price Momentum?
Is Clinigen Group undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CLIN (£6) is trading below our estimate of fair value (£11.19)
Significantly Below Fair Value: CLIN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CLIN's PE Ratio (61.8x) is in line with the UK Life Sciences industry average.
PE vs Market: CLIN is poor value based on its PE Ratio (61.8x) compared to the UK market (23.6x).
Price to Earnings Growth Ratio
PEG Ratio: CLIN is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: CLIN is good value based on its PB Ratio (1.8x) compared to the GB Life Sciences industry average (4.2x).
How is Clinigen Group forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLIN's forecast earnings growth (31.4% per year) is above the savings rate (0.9%).
Earnings vs Market: CLIN's earnings (31.4% per year) are forecast to grow faster than the UK market (14.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CLIN's revenue (10.1% per year) is forecast to grow faster than the UK market (4.7% per year).
High Growth Revenue: CLIN's revenue (10.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CLIN's Return on Equity is forecast to be low in 3 years time (16.3%).
How has Clinigen Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CLIN has a large one-off loss of £34.1M impacting its December 31 2020 financial results.
Growing Profit Margin: CLIN's current net profit margins (2.5%) are lower than last year (2.9%).
Past Earnings Growth Analysis
Earnings Trend: CLIN has become profitable over the past 5 years, growing earnings by 9.7% per year.
Accelerating Growth: CLIN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CLIN had negative earnings growth (-8.5%) over the past year, making it difficult to compare to the Life Sciences industry average (-8.5%).
Return on Equity
High ROE: CLIN's Return on Equity (2.9%) is considered low.
How is Clinigen Group's financial position?
Financial Position Analysis
Short Term Liabilities: CLIN's short term assets (£235.6M) exceed its short term liabilities (£136.2M).
Long Term Liabilities: CLIN's short term assets (£235.6M) do not cover its long term liabilities (£447.6M).
Debt to Equity History and Analysis
Debt Level: CLIN's debt to equity ratio (89.6%) is considered high.
Reducing Debt: CLIN's debt to equity ratio has increased from 48% to 89.6% over the past 5 years.
Debt Coverage: CLIN's debt is well covered by operating cash flow (21.6%).
Interest Coverage: CLIN's interest payments on its debt are well covered by EBIT (5.9x coverage).
What is Clinigen Group current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CLIN's dividend (1.27%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.31%).
High Dividend: CLIN's dividend (1.27%) is low compared to the top 25% of dividend payers in the UK market (4%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, CLIN has been paying a dividend for less than 10 years.
Growing Dividend: CLIN's dividend payments have increased, but the company has only paid a dividend for 8 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (78.4%), CLIN's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: CLIN's dividends in 3 years are forecast to be thoroughly covered by earnings (13.7% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Shaun Chilton (53 yo)
Mr. Shaun Edward Chilton has been the Chief Executive Officer of Clinigen Group Plc since November 11, 2016 & has the responsibility for the Group achieving its KPIs and plays a central role in setting the...
CEO Compensation Analysis
Compensation vs Market: Shaun's total compensation ($USD2.07M) is above average for companies of similar size in the UK market ($USD976.57K).
Compensation vs Earnings: Shaun's compensation has been consistent with company performance over the past year.
Experienced Management: CLIN's management team is considered experienced (4.6 years average tenure).
Experienced Board: CLIN's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Clinigen Group plc's company bio, employee growth, exchange listings and data sources
- Name: Clinigen Group plc
- Ticker: CLIN
- Exchange: AIM
- Founded: 2008
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£797.474m
- Shares outstanding: 133.02m
- Website: https://www.clinigengroup.com
Number of Employees
- Clinigen Group plc
- Pitcairn House
- Crown Square
- DE14 2WW
- United Kingdom
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segmen...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/31 17:58|
|End of Day Share Price||2021/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.